Members of the Cancer Genome Atlas have described driver mutations and potential drug targets detected in a common form of lung cancer called lung adenocarcinoma. They identified new and known lung cancer driver genes through an integrated DNA sequence, RNA sequence, microRNA sequence, copy number, methylation, and proteomic analyses of tumor and normal samples from 230 individuals with the disease. In particular, mutations tended to turn up in genes such as EGFR, RBM10, NF1, MET, ERBB2, MGA, and RIT1.
Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes. The tests will identify patients who are likely to experience statin-induced muscle pain or are at risk of experiencing muscle injury. They plan to market Genomas' SINM PhyzioType System for optimizing treatments on AutoGenomics' Infiniti platform.
The NIH will pump up to $24 million into five research projects that will launch the second phase of the Alzheimer's Disease Sequencing Project, a core component of the Obama Administration's National Plan to Address Alzheimer's Disease. Around $12.6 million will fund the Consortium for Alzheimer's Sequence Analysis, a group of five universities that will analyze whole exome and whole genome sequence data from 6,000 volunteers with AD and genomic data from 111 large families that include multiple members with AD.
This online seminar will discuss the discovery and evaluation of gene expression signatures associated with cancer treatment outcomes. These presentations will provide an overview of the promise of tumor microenvironment profiling in the radiation oncology setting, as well as the challenges in applying genomic methods to biomarker discovery.